High sugar investigation
"diabetes mellitus"[MeSH Terms] AND "diagnosis"[MeSH Terms]
diabetes diagnosis criteria 2025 ADA guidelines HbA1c fasting glucose OGTT
| Risk Factor Category | Examples |
|---|---|
| Family history | First- or second-degree relative with T2DM |
| High-risk ethnicity | African American, Latino, Native American, Asian American, Pacific Islander |
| Metabolic | Hypertriglyceridemia (≥250 mg/dL), low HDL (≤35 mg/dL), hypertension ≥130/80 mmHg |
| History | Previous GDM, history of CVD |
| Lifestyle | Physical inactivity |
| Clinical signs | Acanthosis nigricans, PCOS, hepatic steatosis |
| Test | Normal | Prediabetes | Diabetes |
|---|---|---|---|
| Fasting Plasma Glucose (FPG) | <100 mg/dL (<5.6 mmol/L) | 100–125 mg/dL (IFG) | ≥126 mg/dL (≥7.0 mmol/L) |
| 2-hr 75-g OGTT | <140 mg/dL | 140–199 mg/dL (IGT) | ≥200 mg/dL (≥11.1 mmol/L) |
| HbA1c | <5.7% | 5.7–6.4% (39–46 mmol/mol) | ≥6.5% (≥48 mmol/mol) |
| Random Plasma Glucose | — | — | ≥200 mg/dL with symptoms |
Confirmation rule: Diagnosis requires two abnormal tests (from the same or separate samples) — except when random glucose ≥200 mg/dL in a patient with classic polyuria/polydipsia/weight loss (no repeat needed).
⚠️ Transient hyperglycemia from acute illness (infection, burns, trauma) due to counter-regulatory hormones (catecholamines, cortisol) must resolve before re-testing for definitive diagnosis.
| Feature | HbA1c | Plasma Glucose |
|---|---|---|
| Fasting required? | No | Yes (FPG/OGTT) |
| Within-patient variability | Low | High (affected by diet, stress, diurnal rhythm) |
| Standardization | Well-standardized (NGSP/DCCT) | Variable across labs |
| Limitations | Falsely low in haemolytic anaemia, haemoglobinopathies, iron deficiency; falsely high in iron deficiency (some assays) | Influenced by acute illness |
| Sensitivity for prediabetes | Moderate (lower sensitivity, high specificity) | Higher sensitivity (especially OGTT) |
| Type | Key Features | Additional Workup |
|---|---|---|
| T1DM | Younger, lean, acute onset, ketosis-prone | GAD65, IA-2, ZnT8 autoantibodies; C-peptide (low/absent) |
| T2DM | Older, obese, insidious onset, metabolic syndrome | C-peptide (normal/elevated); lipid panel; renal function |
| MODY | Strong family history, non-obese, young onset | Genetic testing (HNF1A, GCK mutations etc.) |
| Secondary | Pancreatitis, haemochromatosis, steroids, acromegaly, Cushing | Directed by clinical context (amylase, ferritin, cortisol, IGF-1) |
| Investigation | Purpose |
|---|---|
| HbA1c (if not used for diagnosis) | Baseline glycaemic control |
| Fasting lipid panel | Cardiovascular risk |
| Serum creatinine + eGFR | Renal baseline |
| Urine albumin:creatinine ratio (UACR) | Early nephropathy |
| LFTs | Hepatic steatosis association |
| TSH | T1DM/autoimmune association; T2DM comorbidity |
| Blood pressure | Cardiovascular risk stratification |
| Dilated fundoscopy | Baseline retinopathy |
| Foot examination | Neuropathy/vascular baseline |
Incidental/screening high glucose
↓
Asymptomatic? → Confirm with 2nd test (same or different modality)
Symptomatic + random ≥200? → Diagnose directly
↓
Both/confirmed abnormal → Diagnose Diabetes
One borderline → Consider OGTT for definitive classification
↓
HbA1c 5.7–6.4% / FPG 100–125 / OGTT 140–199 → Prediabetes
↓
Classify type → Initiate targeted workup + treatment
Bilateral pedal edema diagnosis
bilateral pedal edema causes diagnosis clinical approach 2024 2025
bilateral lower limb edema diagnosis causes investigation workup